Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R) agonist, ...

Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.

Insulin and leptin receptors are present in hypothalamic regions that control energy homeostasis, and these hormones reduce food intake and body weight in lean, but not obese, Zucker rats. Here we ...

Cortisol is a hormone that naturally occurs in your body, but can cortisol supplements really reduce stress? We asked experts ...

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

Researchers led by the University of Geneva and École Polytechnique Fédérale de Lausanne report that neural anticipation of ...

At the same time, a growing body of research is documenting the negative health consequences of higher stress levels, which ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

Cynthia Donovan became increasingly focused on diet and exercise before her wedding. After missing her period for many months ...

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...